{"id":"W2166262263","doi":"10.1016/s0140-6736(12)60868-x","title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2960,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"GlaxoSmithKline","keywords":"Dabrafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Hazard ratio; Clinical endpoint; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Metastatic melanoma; Chemotherapy; Cancer; Vemurafenib; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001910806,0.002338361,0.003907179,0.0003788381,0.0004019862,0.001359114,0.0007950622,0.001760307,0.006919031],"category_scores_gemma":[0.001928364,0.0006765875,0.003014379,0.0005694974,0.001027863,0.001218253,0.0004155621,0.003091379,0.001062288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001146219,"about_ca_system_score_gemma":0.001023149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001832075,"about_ca_topic_score_gemma":0.004288086,"domain_scores_codex":[0.9992804,0.0003764146,0.00003670713,0.0001164286,0.00005032648,0.0001398488],"domain_scores_gemma":[0.9992912,0.0002016753,0.0001570873,0.00005695591,0.00005337944,0.0002396788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805256,0.001041153,0.0004620246,0.001060389,0.001895935,0.00005918761,0.00003644458,0.0003910434,0.001873811,0.000132373,0.001576502,0.01094555],"study_design_scores_gemma":[0.9840518,0.01310418,0.0009076378,0.00004604607,0.0006189765,0.00004051625,0.00001977099,0.000210248,0.0001218142,0.0001894797,0.0006753111,0.00001422721],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9521987,0.0296333,0.001939182,0.003499237,0.001968201,0.004019842,0.003185037,0.0002624988,0.003294024],"genre_scores_gemma":[0.9695686,0.0119523,0.002314817,0.003066847,0.000713717,0.003937231,0.002279461,0.00005904748,0.00610787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006919031,"threshold_uncertainty_score":0.02314645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05743917274431475,"score_gpt":0.3392784182895699,"score_spread":0.2818392455452552,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}